Oxford’s involvement in the COMP006 study (psilocybin for depression) has reached an important milestone, with the final participant completing their last study visit.
Delivered at the NIHR Clinical Research Facility (CRF): Oxford Health, COMP006 forms part of Compass Pathways’ international Phase 3 programme evaluating COMP360 psilocybin, administered alongside psychological support, for people with treatment-resistant depression (TRD). TRD is generally defined as depression that has not responded adequately to at least two antidepressant treatments.
Since opening the study in Oxford in 2024, the team has supported participants through treatment sessions, follow-up assessments and long-term monitoring.
While the final analysis is ongoing, Compass Pathways has shared a series of interim updates from the study. In February 2026, the company reported a statistically significant reduction in depression symptom severity at six weeks for participants receiving two doses of COMP360 25mg compared with the 1mg comparator group. They also confirmed ongoing discussions with the US Food and Drug Administration (FDA) as part of its regulatory submission process.
The completion of the final participant’s visit marks the end of Oxford’s active delivery phase and the beginning of the next stage of analysis across the wider international programme.
What happens next?
Researchers will continue to analyse longer-term data from the study, including outcomes from later phases of the trial. Any future regulatory decisions will be made by the relevant authorities following review of the full evidence.
For participants, staff and collaborators who have contributed to COMP006, the final visit represents the culmination of several years of work and an important moment in the search for new treatment options for people whose depression has not responded to currently available therapies. Building on their expertise in novel treatments in depression, the CRF: Oxford Health is planning further studies in a variety of novel treatments, including psychedelic treatments, for different mental health conditions.
Dr Katharine Smith, Consultant Psychiatrist at Oxford Health NHS Foundation Trust and Principal Investigator for COMP006 at Oxford, said:
“Reaching the final participant visit is an important milestone for everyone involved in this study. We are incredibly grateful to the participants who gave their time and commitment to this research, as well as the dedicated study team who supported them throughout. While further analyses are still ongoing, this marks the completion of a significant phase of work and brings us closer to understanding the potential role this investigational treatment may have for people living with treatment-resistant depression.”
